問卷

TPIDB > Search Result

Search Result

篩選

List

22Cases

2026-05-01 - 2033-12-31

Phase III

Active
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    皮下注射劑 皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2028-03-01

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2029-12-31

Others

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-05-01 - 2028-02-29

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-05-01 - 2027-07-30

Others

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2026-02-01 - 2034-11-14

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2023-05-02 - 2027-03-19

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2017-12-01 - 2025-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

2020-12-21 - 2023-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-09-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3